{
  "created_at": "Thu Jun 24 5:19:43 +0000 2021",
  "id_str": "1407922781162033152",
  "full_text": "In April we wrote that phase-three trials of Sinovac yielded an efficacy rate barely above the 50% threshold set by the WHO for covid-19 vaccines, but were good protection against severe disease and death https://t.co/DkNr6mlNKU",
  "display_text_range": [
    0,
    228
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/DkNr6mlNKU",
        "expanded_url": "https://econ.st/3dpAxNd",
        "display_url": "econ.st/3dpAxNd",
        "indices": [
          205,
          228
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 33,
  "favorite_count": 92,
  "possibly_sensitive": false,
  "original_created_at": "Thu Jun 24 04:45:23 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "4月の記事では、シノバックの第3相試験の結果、有効率はWHOがコビド19ワクチンに設定した基準値の50％をわずかに上回っただけだったが、重篤な疾病や死亡に対する予防効果は高かったと書いた。https://t.co/DkNr6mlNKU"
    },
    {
      "locale": "zh",
      "full_text": "4月，我们写道，Sinovac的第三阶段试验产生的有效率勉强超过世卫组织为covid-19疫苗设定的50%阈值，但对严重疾病和死亡有良好的保护作用https://t.co/DkNr6mlNKU。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "4月，我們寫道，Sinovac的第三階段試驗產生的有效率勉強超過世衛組織爲covid-19疫苗設定的50%閾值，但對嚴重疾病和死亡有良好的保護作用https://t.co/DkNr6mlNKU。"
    }
  ]
}